EUVIMEDEUVIMED entdecken
Multizentrische StudieRandomisierte kontrollierte Studie

Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study

X Chevalier, P Goupille, A D Beaulieu, F X Burch, W G Bensen, T Conrozier, D Loeuille, A J Kivitz, D Silver, B E Appleton

Arthritis Care & Research · 15.03.2009 · 61 (3) · 344-352

DOI: 10.1002/art.24096 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Arthritis Care & Research, online erschienen am 26.02.2009. Verfasst von X Chevalier und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Hospital Henri Mondor, University Paris XII, Créteil, France. xavier.chevalier@hmn.ap-hop-paris.fr. Die Arbeit wurde bisher 499-mal zitiert (Crossref) und nennt 30 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

To evaluate the clinical response, safety, and tolerability of a single intraarticular injection of anakinra in patients with symptomatic osteoarthritis (OA) of the knee.

Methods

Patients with OA of the knee were enrolled in a multicenter, double‐blind, placebo‐controlled study and randomized 2:1:2 to receive a single intraarticular injection of placebo, anakinra 50 mg, or anakinra 150 mg in their symptomatic knee. Patients were evaluated for 12 weeks postinjection. The primary end point was the change in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) score from baseline to week 4. Safety assessments included the evaluation of adverse events (AEs), laboratory tests, and vital signs. Pharmacokinetic parameters were assessed in a subset of patients.

Results

Of 170 patients who enrolled, 160 (94%) completed the study. The mean improvements from baseline to week 4 in the WOMAC score were not statistically different between the placebo group and the patients who received 50 mg of anakinra ( P = 0.67) or 150 mg of anakinra ( P = 0.77). Anakinra was well tolerated. No withdrawals due to AEs or serious AEs, and no serious infections or deaths were reported. No clinically significant trends were noted in laboratory values or vital signs. Pharmacokinetic parameters demonstrated that the mean terminal half‐life of anakinra in serum after intraarticular injection was ∼4 hours.

Conclusion

Anakinra was well tolerated as a single 50‐mg or 150‐mg intraarticular injection in patients with OA of the knee. However, anakinra was not associated with improvements in OA symptoms compared with placebo.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAgedAged, 80 and overAntirheumatic AgentsDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansInjections, Intra-ArticularInterleukin 1 Receptor Antagonist ProteinMaleMiddle AgedOsteoarthritis, KneeSeverity of Illness Index

Substanzen

Antirheumatic AgentsInterleukin 1 Receptor Antagonist Protein

Autor:innen und Institutionen

  • Department of Rheumatology, Hospital Henri Mondor, University Paris XII, Créteil, France. xavier.chevalier@hmn.ap-hop-paris.fr

Zitieren

APA

Chevalier, X., Goupille, P., Beaulieu, A. D., Burch, F. X., Bensen, W. G., Conrozier, T., Loeuille, D., Kivitz, A. J., Silver, D., & Appleton, B. E. (2009). Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis Care & Research, 61(3), 344-352. https://doi.org/10.1002/art.24096

Vancouver

Chevalier X, Goupille P, Beaulieu AD, Burch FX, Bensen WG, Conrozier T, et al. Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study. Arthritis Care & Research. 2009;61(3):344-352. doi:10.1002/art.24096

BibTeX
@article{Chevalier2009,
  author = {Chevalier, X and Goupille, P and Beaulieu, A D and Burch, F X and Bensen, W G and Conrozier, T and Loeuille, D and Kivitz, A J and Silver, D and Appleton, B E},
  title = {Intraarticular injection of anakinra in osteoarthritis of the knee: A multicenter, randomized, double‐blind, placebo‐controlled study},
  journal = {Arthritis Care & Research},
  year = {2009},
  volume = {61},
  number = {3},
  pages = {344--352},
  doi = {10.1002/art.24096}
}
Kostenlos starten →